About SELECT clinical study SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for the prevention of major adverse cardiac events (MACE) in people with overweight or obesity and established cardiovascular disease with no prior history of diabetes
It also changes the way your brain responds to food cues, reducing cravings for high-fat, energy-dense foods
Osbert Fernandez MD, FACOG, FAAFP, Medical Director Austin Marie Jacobus RN, MSN, NP-C, VP Clinical
In 2017, the World Health Organization estimated that 10 percent of drugs in developing countries were either substandard or falsified